AbbVie next-generation hepatitis C dr... - HFI Connect - Hep...

HFI Connect - Hepatitis

959 members1,215 posts

AbbVie next-generation hepatitis C drugs look promising in early studies

mwright profile image
0 Replies

AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in patients with genotype 1 chronic hepatitis C in a three-day monotherapy study, as well as potent and synergistic activity against multiple HCV genotypes in laboratory replicon studies, according to presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting held recently in Boston. Read here: aidsmap.com/page/2940936/

Written by
mwright profile image
mwright
To view profiles and participate in discussions please or .
Read more about...